Denmark · Biotechnology startup
Denmark · Synklino
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection.
Funding reportedLast round: Series A
Follow Synklino and see its new rounds in your feed.Start following
What company datasets say Synklino raised
Funding, as reported
Reported in all32Min the source's currency
Last roundSeries A
Investors listed5
Founders and team
From Synklino's own website: 2 founders, 5 on the team.
Thomas KledalCEO & Co-founder
Mette RosenkildeCo-founder
- Carit Jacques AndersenCFO
- Jette Wagtberg SenCOO
- Frederika CalssonProject Director
- John HaurumChairman
- John LambertEVP, CSO, and Distinguished Research Fellow at Immunogen
AdvisersMads Lacoppidan
Biotechnology in Denmark
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Synklino in front of investors. Or tell us what we have wrong.